ARVN
ARVINAS, INC.
NASDAQ · Healthcare · Biotechnology · US
$7.42
+4.65%Next report
Analyst consensus
- Next report date
- Feb 23, 2027
- EPS estimate
- -$0.77
- Revenue estimate
- $11.9M
Latest reported
- Last report date
- Nov 3, 2026
- EPS actual
- -$0.82
- EPS estimate
- -$0.92
- Revenue actual
- $500.0K
- Revenue estimate
- $12.4M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +176.4%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Strong Buy
- Price target
- $16
- PT range
- $13 – $21
- Analysts
- 4
4 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 3, 2026 | -$0.92 | -$0.82 | Beat 10.65% | $500.0K |
| Aug 4, 2026 | -$0.37 | $2.58 | Beat 789.64% | $249.7M |
| May 12, 2026 | -$0.95 | -$0.90 | Beat 5.26% | $15.6M |
| Feb 24, 2026 | -$0.55 | -$1.10 | Miss -100.00% | $9.5M |
| Nov 5, 2025 | -$0.75 | -$0.48 | Beat 36.00% | $41.9M |
| Aug 6, 2025 | -$0.87 | -$0.84 | Beat 3.45% | $22.4M |
| May 1, 2025 | -$0.86 | $1.14 | Beat 232.56% | $188.8M |
| Feb 27, 2024 | -$1.33 | -$2.53 | Miss -90.23% | $43.1M |
| May 5, 2023 | -$1.46 | -$1.54 | Miss -5.48% | $32.5M |
| Feb 23, 2023 | -$1.04 | -$1.56 | Miss -50.00% | $38.0M |
| Aug 4, 2022 | -$1.02 | -$1.32 | Miss -29.41% | $31.3M |
| May 5, 2022 | -$0.85 | -$1.20 | Miss -41.18% | $24.2M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 23, 2027